CBB 1
/ Changchun BCHT Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 12, 2024
Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Changchun BCHT Biotechnology Co.
New P2 trial • Infectious Disease
April 27, 2023
Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1
(clinicaltrials.gov)
- P1 | N=152 | Not yet recruiting | Sponsor: Changchun BCHT Biotechnology Co.
New P1 trial • Infectious Disease
1 to 2
Of
2
Go to page
1